Dr. William J. Muller, MD, PHD
Pediatric Infectious Disease (Pediatric Infectious Diseases Physician)
225 E Chicago Ave, Box 20
Chicago, IL 60611
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2006
Licensed in Illinois since 2007, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Infectious Diseases Physician primary
IL license 036119141 (first issued 2007; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Lurie Children's Medical Group Inc. (151 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $128,272 in research payments for these studies, mostly to the institutions running them.
- A Phase 1, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravenous and Oral Doses of Omadacycline in Pediatric Subjects with Suspected or Confirmed Bacterial Infe…
Paratek Pharmaceuticals, Inc. - A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
ModernaTX, Inc. · Completed · NCT05436834 - A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole POS, MK-5592 Intravenous and Powder for Oral Suspension Formulations in Pediatric Pa…
Merck Sharp & Dohme LLC - A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole POS, MK-5592 in Pediatric Participants Aged 2 to less than 18 Years With Invasive Aspergillosis
Merck Sharp & Dohme LLC - Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
Melinta Therapeutics, LLC · Completed · NCT02687906 - A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial To Study The Safety and Efficacy of Ceftolozane,Tazobactam MK-7625A Versus Meropenem In Pedicatric Subjects With Complicate…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.